INO

1.93

1.53% -0.03

Pre-mercato: 1.99 0.06 +3.11%

Inovio Pharmaceuticals Inc (INO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$1.96

Aprire:

$1.95

Volume 24 ore:

547.29K

Relative Volume:

0.84

Capitalizzazione di mercato:

$82.52M

Reddito:

$832.00K

Utile/perdita netta:

$-135.12M

Rapporto P/E:

-0.3169

EPS:

-6.09

Flusso di cassa netto:

$-124.69M

1 W Prestazione:

-3.50%

1M Prestazione:

-2.03%

6M Prestazione:

+7.82%

1 anno Prestazione:

-76.14%

Intervallo 1D:

$1.86

$1.96

Intervallo di 1 settimana:

$1.86

$2.02

Portata 52W:

$1.42

$12.33

Inovio Pharmaceuticals Inc Stock (INO) Company Profile

Nome

Inovio Pharmaceuticals Inc

Settore

Healthcare (1170)

Industria

Biotechnology (662)

Telefono

(858) 410-3134

Indirizzo

660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA

Dipendente

134

Cinguettio

@inoviopharma

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

INO's Discussions on Twitter

Confronta INO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
INO Inovio Pharmaceuticals Inc	1.93	82.52M	832.00K	-135.12M	-124.69M	-6.09
VRTX Vertex Pharmaceuticals Inc	443.54	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	511.92	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	313.13	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	540.76	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	257.51	28.51B	3.81B	-644.79M	-669.77M	-6.24

Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-05-14	Iniziato	Stephens	Overweight
2024-01-25	Aggiornamento	Oppenheimer	Perform → Outperform
2022-11-09	Downgrade	Maxim Group	Buy → Hold
2022-11-01	Downgrade	BofA Securities	Neutral → Underperform
2022-07-19	Ripresa	RBC Capital Mkts	Sector Perform
2022-05-11	Downgrade	Oppenheimer	Outperform → Perform
2022-01-21	Aggiornamento	BofA Securities	Underperform → Neutral
2021-12-29	Ripresa	Jefferies	Hold
2021-09-10	Downgrade	BofA Securities	Neutral → Underperform
2021-06-24	Iniziato	Jefferies	Hold
2021-03-23	Iniziato	BofA Securities	Neutral
2021-02-12	Iniziato	Oppenheimer	Outperform
2020-11-17	Downgrade	ROTH Capital	Neutral → Sell
2020-11-10	Aggiornamento	ROTH Capital	Sell → Neutral
2020-09-28	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2020-09-28	Aggiornamento	Maxim Group	Hold → Buy
2020-07-01	Downgrade	Maxim Group	Buy → Hold
2020-07-01	Downgrade	ROTH Capital	Neutral → Sell
2020-06-29	Downgrade	H.C. Wainwright	Buy → Neutral
2020-06-26	Downgrade	Stifel	Buy → Hold
2020-05-21	Iniziato	The Benchmark Company	Buy
2020-04-30	Downgrade	ROTH Capital	Buy → Neutral
2020-03-13	Downgrade	Piper Sandler	Overweight → Neutral
2020-03-13	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2019-12-19	Iniziato	ROTH Capital	Buy
2018-02-15	Reiterato	Maxim Group	Buy
2017-10-18	Iniziato	RBC Capital Mkts	Outperform
2017-09-06	Iniziato	Citigroup	Buy
2017-06-08	Aggiornamento	Piper Jaffray	Neutral → Overweight
2017-05-24	Reiterato	Maxim Group	Buy
2017-03-16	Aggiornamento	Maxim Group	Hold → Buy
2017-03-16	Downgrade	Piper Jaffray	Overweight → Neutral

Mostra tutto

Inovio Pharmaceuticals Inc Borsa (INO) Ultime notizie

Jun 11, 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2025 Earnings Call Transcript - MSN

Jun 11, 2025

Jun 09, 2025

Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - AllSides

Jun 09, 2025

Human DNA Vaccines Market Set to Witness Breakthrough Advances - openPR.com

Jun 09, 2025

Jun 07, 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Position Boosted by Bank of America Corp DE - Defense World

Jun 07, 2025

Jun 03, 2025

Deutsche Bank AG Has $164,000 Stock Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World

Jun 03, 2025

Jun 01, 2025

Northern Trust Corp Grows Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World

Jun 01, 2025

May 30, 2025

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

May 30, 2025

May 27, 2025

Inovio’s SWOT analysis: dna immunotherapy firm faces crucial year for stock - Investing.com Australia

May 27, 2025

May 23, 2025

Inovio shareholders approve board nominees and proposals By Investing.com - Investing.com Canada

May 23, 2025

May 22, 2025

Inovio shareholders approve board nominees and proposals - Investing.com Australia

May 22, 2025

Inovio outlines BLA submission timeline for INO-3107 and reports $68.4M cash position while advancing DNA medicine pipeline - MSN

May 15, 2025

May 14, 2025

Inovio Pharmaceuticals (INO) Maintains Sector Perform Rating by RBC Capital | INO Stock News - GuruFocus

May 14, 2025

Oppenheimer cuts Inovio stock price target to $13 By Investing.com - Investing.com Nigeria

May 14, 2025

INO Reports Strong Q1 Revenue, Progress on INO-3107 Submission | - GuruFocus

May 14, 2025

Inovio (INO) Receives Revised Price Target from Oppenheimer | IN - GuruFocus

May 14, 2025

Inovio Pharmaceuticals: Hold Rating Due to Financial Losses and Uncertain Development Timeline - TipRanks

May 14, 2025

Inovio stock holds $12 target, JMP affirms Market Outperform By Investing.com - Investing.com Canada

May 14, 2025

Inovio stock holds $12 target, JMP affirms Market Outperform - Investing.com Australia

May 14, 2025